反应详情

Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (Example 135) from (1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (Intermediate 34: 450 mg, 1.71 mmol) and 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 349 mg, 1.71 mmol) except after the reaction was complete it was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit. The organics were loaded directly on to a cation/anion mixed mode cartridge, eluted with DCM and concentrated in vacuo. The resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate/petrol) and then purified by reverse phase column chromatography (C18 silica, 0-100% water (0.05% ammonia)/acetonitrile) to afford the title compound.

1. customPrepared
2. customwas partitioned between DCM
3. filtrationa saturated solution of sodium bicarbonate, filtered through a hydrophobic frit
4. additionmixed mode cartridge
5. washeluted with DCM
6. concentrationconcentrated in vacuo
7. customThe resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate/petrol)
8. custompurified by reverse phase column chromatography (C18 silica, 0-100% water (0.05% ammonia)/acetonitrile)